Citations

Showing 10 of 108162 citations.

Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation
Benjamin, Emelia J. , Buxton, Alfred E. , Calkins, Hugh , Chung, Mina K. , Curtis, Anne B. , Desvigne‐Nickens, Patrice , Packer, Douglas L. , Piccini, Jonathan P. , Rosenberg, Yves , Russo, Andrea M. , Wang, Paul J. , Cooper, Lawton S. , Go, Alan S. , Marrouche, Nassir F. , Hills, Melanie True, Zieman, Susan J., Benjamin, Emelia J , Al‐Khatib, Sana M. , Jaı̈s, Pierre , Healey, Jeff S. , Link, Mark S. , Noseworthy, Peter A. , Sanders, Prashanthan , Yao, Xiaoxi

Mayo Clinic

Circulation | November 20, 2019 | Volume: 141 | Issue: 6 | Pages: 482-492

10.1161/circulationaha.119.042706 | PMID 31744331 Get It

Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ablation significantly reduced cardiovascular hospitalizations. Despite the existing data on AF catheter ablation, numerous knowledge gaps remain concerning this intervention. This report is based on a recent virtual workshop convened by the National Heart, Lung, and Blood Institute to identify key research opportunities in AF ablation. We outline knowledge gaps related to emerging technologies, the relationship between cardiac structure and function and the success of AF ablation in patient subgroups in whom clinical benefit from ablation varies, and potential platforms to advance clinical research in this area. This report also considers the potential value and challenges of a sham ablation randomized trial. Prioritized research opportunities are identified and highlighted to empower relevant stakeholders to collaborate in designing and conducting effective, cost-efficient, and transformative research to optimize the use and outcomes of AF ablation.
Personal-Professional Boundaries and Ethical Issues in Palliative Care
Swetz, Keith M. , Frazier, Sandra L., Richardson, Jarrett W., Shanafelt, Tait D. , Shanafelt, Tait D

Mayo Clinic

The American Journal of Bioethics | November 20, 2019 | Volume: 19 | Issue: 12 | Pages: 60-62

10.1080/15265161.2019.1675800 | PMID 31971083 Get It

A Comparison of Revision Rates and Patient-Reported Outcomes for a 2-Level Posterolateral Fusion Augmented With Single Versus 2-Level Transforaminal Lumbar Interbody Fusion
Kaye, I. David , Fang, Terry, Wagner, Scott C. , Butler, Joseph S. , Sebastian, Arjun S. , Morrissey, Patrick B. , Levine, Marc J., Vaccaro, Alexander R. , Hilibrand, Alan S. , Sebastian, Arjun, Vaccaro, Alex R , Fang, Terry, Levine, Marc J.

Mayo Clinic

Global Spine Journal | November 20, 2019 | Volume: 10 | Issue: 8 | Pages: 958-963

10.1177/2192568219889360 | PMID 32875833 Get It

Study Design: Retrospective, single institution, multisurgeon case control series. Objective: To determine whether there are differences in reoperation rates or outcomes for patients undergoing 2-level posterolateral fusion (PLF) augmented by a transforaminal lumbar interbody fusion (TLIF) at only one of the levels or at both. Methods: A total of 416 patients were identified who underwent 2-level PLF with a TLIF at either one of those levels (n = 183) or at both (n = 233) with greater than 1-year follow-up. Demographic, surgical, radiographic, and clinical data was reviewed for each patient. These included age, sex, race, body mass index, smoking status, Charleston Comorbidity Index, operative time, estimated blood loss, length of stay, and patient-reported outcome measures. Results: Each cohort underwent 24 reoperations. Although the number of overall reoperations was not significantly different ( P > .05), among the reoperation types, there were significantly more reoperations for adjacent segment disease in the 2-level group compared to the 1-level group (19 vs 12, P = .04). There was no difference in reoperation for pseudarthrosis between the groups ( P > .05). Although both groups experienced significant improvements in Oswestry Disability Index ( P < .001) and Short Form–12 health questionnaire ( P < .001), there were no differences between improvements for 1- versus 2-level cohorts. Conclusions: For patients undergoing 2-level PLF in the setting of a TLIF, using a TLIF at one versus both levels does not seem to influence reoperation rates or outcomes. However, reoperation rates for adjacent segment disease are increased in the setting of a 2-level PLF augmented by a 2-level TLIF.
Occipital Neuralgia Treated With Acupuncture: A Case Report
Mallory, Molly J., Bauer, Brent A. , Chon, Tony Y. , Mallory, Molly , Bauer, Brent, Chon, Tony

Mayo Clinic

Global Advances in Health and Medicine | November 20, 2019 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2164956119890546 | PMID 31819833 Get It

We present a case report of a patient whose occipital neuralgia symptoms were substantially improved after a single acupuncture treatment with complete resolution after only a short course of care. The patient, a 78-year-old woman, presented to our institution’s neurology department with symptoms of posterior neck pain and electrical sensations in her head which had been present for more than 1 year. With a desire to avoid pharmacologic intervention or invasive procedures, the patient requested acupuncture treatment. The patient received 5 acupuncture treatments over the course of 8 days with substantial resolution of her head pain after a single treatment. This case is suggestive that acupuncture may be a beneficial treatment for patients with occipital neuralgia.
Tuberculosis presenting as dacryoadenitis in the USA
Powers, H. R. , Diaz, Mark Anthony , Mendez, Julio, Powers, Harry Ross, Mendez, Julio C, Powers, Harry R

Mayo Clinic

BMJ Case Reports | November 20, 2019 | Volume: 12 | Issue: 11 | Pages: e231694

10.1136/bcr-2019-231694 | PMID 31748361 Get It

A 25-year-old Filipino woman living in the USA was evaluated for a 5-month history of left eye pain and a subsequent orbital mass. Histopathological analysis of the lacrimal mass showed a mixed inflammatory process with necrotising granulomas and positive cultures for Mycobacterium tuberculosis. She was treated with antituberculosis therapy, with resolution of symptoms. Tuberculosis dacryoadenitis is extremely rare in the USA and other developed countries. It requires a high degree of clinical suspicion with special attention to the patient’s history to make the correct diagnosis. It can be treated successfully with antituberculosis therapy.
Citation Skew in Plastic Surgery Journals: Does the Journal Impact Factor Predict Individual Article Citation Rate?
Asaad, Malke , Kallarackal, Austin Paul, Meaike, Jesse D. , Rajesh, Aashish , Azevedo, Rafael Ulysses de, Tran, Nho V. , Meaike, Jesse, de Azevedo, Rafael U

Mayo Clinic

Aesthetic Surgery Journal | November 20, 2019 | Volume: 40 | Issue: 10 | Pages: 1136-1142

10.1093/asj/sjz336 | PMID 31745562 Get It

AbstractBackgroundCitation skew refers to the unequal distribution of citations to articles published in a particular journal.ObjectivesWe aimed to assess whether citation skew exists within plastic surgery journals and to determine whether the journal impact factor (JIF) is an accurate indicator of the citation rates of individual articles.MethodsWe used Journal Citation Reports to identify all journals within the field of plastic and reconstructive surgery. The number of citations in 2018 for all individual articles published in 2016 and 2017 was abstracted.ResultsThirty-three plastic surgery journals were identified, publishing 9823 articles. The citation distribution showed right skew, with the majority of articles having either 0 or 1 citation (40% and 25%, respectively). A total of 3374 (34%) articles achieved citation rates similar to or higher than their journal’s IF, whereas 66% of articles failed to achieve a citation rate equal to the JIF. Review articles achieved higher citation rates (median, 2) than original articles (median, 1) (P &lt; 0.0001). Overall, 50% of articles contributed to 93.7% of citations and 12.6% of articles contributed to 50% of citations. A weak positive correlation was found between the number of citations and the JIF (r = 0.327, P &lt; 0.0001).ConclusionsCitation skew exists within plastic surgery journals as in other fields of biomedical science. Most articles did not achieve citation rates equal to the JIF with a small percentage of articles having a disproportionate influence on citations and the JIF. Therefore, the JIF should not be used to assess the quality and impact of individual scientific work.
The GEF‐H1/PKD3 signaling pathway promotes the maintenance of triple‐negative breast cancer stem cells
Lungu, Cristiana , Tamas, Raluca , Berreth, Hannah, Rathert, Philipp , Störz, Peter , Olayioye, Monilola A. , Haußer, Angelika , Olayioye, Monilola A , Hausser, Angelika , Lieb, Wolfgang

Mayo Clinic

International Journal of Cancer | November 20, 2019 | Volume: 146 | Issue: 12 | Pages: 3423-3434

10.1002/ijc.32798 | PMID 31745977 Get It

Protein kinase D3 (PKD3) is upregulated in triple‐negative breast cancer (TNBC) and associated with cell proliferation and metastasis development but its precise pro‐oncogenic function is unknown. Here we show that PKD3 is required for the maintenance of the TNBC stem cell population. The depletion of PKD3 in MDA‐MB‐231 cells reduced the cancer stem cell frequency in vitro and tumor initiation potential in vivo. We further provide evidence that the RhoGEF GEF‐H1 is upstream of PKD3 activation in TNBC stem cells. Most importantly, pharmacological PKD inhibition in combination with paclitaxel synergistically decreased oncosphere and colony formation efficiency in vitro and tumor recurrence in vivo. Based on our results we propose that targeting the GEF‐H1/PKD3 signaling pathway in combination with chemotherapy might provide an effective therapeutic option for TNBC.
Response to: Some Questions About the Article “The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report”
Ebeling, Peter R. , Bauer, Douglas C. , Eastell, Richard , Fink, Howard A , Giangregorio, Lora , Guañabens, Núria , Kado, Deborah M. , Kallmes, David F. , Katzman, Wendy B. , Rodríguez, Alexander J. , Wermers, Robert A. , Wilson, H Alexander, Bouxsein, Mary , Ebeling, Peter R , Bauer, Douglas C , Fink, Howard A , Giangregorio, Lora , Kallmes, David, Wermers, Robert, Bouxsein, Mary L , Buchbinder, Rachelle , Åkesson, Kristina

Mayo Clinic

Journal of Bone and Mineral Research | November 19, 2019 | Volume: 35 | Issue: 1 | Pages: 212-213

10.1002/jbmr.3906 | PMID 31743502 Get It

A survey of surface imaging use in radiation oncology in the United States
Padilla, Laura , Havnen‐Smith, Amanda, Cerviño, Laura , Al‐Hallaq, Hania

Mayo Clinic

Journal of Applied Clinical Medical Physics | November 19, 2019 | Volume: 20 | Issue: 12 | Pages: 70-77

10.1002/acm2.12762 | PMID 31743588 Get It

AbstractSurface imaging (SI) has been rapidly integrated into radiotherapy clinics across the country without specific guidelines and recommendations on its commissioning and use aside from vendor‐provided information. A survey was created under the auspices of AAPM TG‐302 to assess the current status of SI to identify if there is need for formal guidance. The survey was designed to determine the institutional setting of responders, availability and length of its use, commissioning procedures, and clinical applications. This survey was created in REDCap, and approved as IRB exempt to collect anonymized data. Questions were reviewed by multiple physicists to ensure concept validity and piloted by a small group of independent physicists to ensure process validity. All full members of AAPM self‐identified as “therapy” or “other” were sent the survey link by email. The survey was active from February to March 2018. Of 3677 members successfully contacted, 439 completed responses; the summary of these responses provides insight on current surface imaging clinical practices, though they should not be assumed to be representative of radiation oncology as a whole. Results showed that 53.3% of respondents have SI in their clinics, mostly in treatment rooms, rarely in simulation rooms. Half of those without SI plan on purchasing it within 3 years. Over 10% have SI but do not use it clinically, 36.8% classify themselves as “expert” users, and 85.5% agreed/strongly agreed that SI guidelines are needed. Initial positioning with SI is most common for breast/chestwall and SRS/SBRT treatments, least common for pediatrics. Use of SI for intra‐fraction monitoring follows a similar distribution. Gating with SI is most prevalent for breast/chestwall (66.0%) but also used in SBRT (33.0%), and non‐SBRT lung/abdomen (<30%) treatments. SI is a rapidly growing technology in the field with widespread use for several anatomic sites. Guidelines and recommendations on commissioning and clinical use are warranted.
MRAS Variants Cause Cardiomyocyte Hypertrophy in Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Higgins, Erin M. , Bos, J. Martijn , Dotzler, Steven M. , Kim, CS John, Ackerman, Michael J. , Bos, Johan M

Mayo Clinic

Circulation: Genomic and Precision Medicine | November 19, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circgen.119.002648 | PMID 31638832 Get It

Background: MRAS was identified recently as a novel Noonan syndrome (NS)-susceptibility gene. Phenotypically, both patients with NS, harboring pathogenic MRAS variants, displayed severe cardiac hypertrophy. This study aimed to demonstrate both the necessity and sufficiency of a patient-specific variant (p.Gly23Val-MRAS) to cause NS through the generation and characterization of patient-specific, isogenic control, and disease modeled induced pluripotent stem cell (iPSC) lines. Methods: iPSCs were derived from a patient with a p.Gly23Val-MRAS variant to assess the effect of MRAS variants on pathogenesis of NS-associated cardiac hypertrophy. CRISPR/Cas9 gene editing was used to correct the pathogenic p.Gly23Val-MRAS variant in patient cells (isogenic control) and to introduce the pathogenic variant into unrelated control cells (disease modeled) to determine the necessity and sufficiency of the p.Gly23Val-MRAS variant to elicit the disease phenotype in iPSC-derived cardiomyocytes (iPSC-CMs). iPSC-CMs were analyzed by microscopy and immunofluroesence, single-cell RNAseq, Western blot, room temperature-quantitative polymerase chain reaction, and live-cell calcium imaging to define an in vitro phenotype of MRAS -mediated cardiac hypertrophy. Results: Compared with controls, both patient and disease modeled iPSC-CMs were significantly larger and demonstrated changes in gene expression and intracellular pathway signaling characteristic of cardiac hypertrophy. Additionally, patient and disease modeled iPSC-CMs displayed impaired Ca 2+ handling, including increased frequency of irregular Ca 2+ transients and changes in Ca 2+ handling kinetics. Conclusions: p.Gly23Val-MRAS is both necessary and sufficient to elicit a cardiac hypertrophy phenotype in iPSC-CMs that includes increased cell size, changes in cardiac gene expression, and abnormal calcium handling-providing further evidence to establish the monogenetic pathogenicity of p.Gly23Val-MRAS in NS with cardiac hypertrophy.